

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 75213

BIOEQUIVALENCE REVIEW(S)

1.1 Schwartz, P

BIOEQUIVALENCY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: ~~75-219~~ and 75-265 APPLICANT: Spear Pharmaceuticals, Inc.

DRUG PRODUCT: Tretinoin Cream, 0.1% and 0.05%, USP

The Division of Bioequivalence has completed its review and has no further questions at this time.

Please note that the bioequivalency comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalency information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,

/S/

Dale P. Conner, Pharm. D.
Director
Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research

BIOEQUIVALENCY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 75-213 and 75-265 APPLICANT: Spear Pharmaceuticals, Inc.

DRUG PRODUCT: Tretinoin Cream, 0.1% and 0.05%, USP

The Division of Bioequivalence has completed its review and has no further questions at this time.

Please note that the bioequivalency comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalency information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,

/S/

Dale P. Conner, Pharm. (D.)
Director
Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research